Lineage Cell Therapeutics, Inc. (LCTX) Operating Margin
- Operating margin · 12 months: Value -205.23%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -205.23% | Operating income / revenue. Period ending 2026-06-30. $-26.85M ÷ $13.08M × 100 ≈ -205.23% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -26.85M USD | Operating Income (Loss) |
| Revenue | 13.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 20.52M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-26.85M | $13.08M | (m) | $20.52M | (m) | -205.23% |
| 2026-03-31 | $-37.71M | $14.78M | (m) | $18.85M | (m) | -255.14% |
| 2025-12-31 | $-36.62M | $14.56M | (m) | $17.73M | (m) | -251.57% |
| 2025-09-30 | $-35.18M | $10.82M | (m) | $12.91M | (m) | -325.27% |
| 2025-06-30 | $-35.23M | $10.91M | (m) | $12.81M | (m) | -322.84% |
| 2025-03-31 | $-21.32M | $9.56M | (m) | $12.58M | (m) | -223.10% |
| 2024-12-31 | $-21.48M | $9.50M | (m) | $12.47M | (m) | -226.11% |
| 2024-09-30 | $-22.73M | $8.72M | (m) | $12.96M | (m) | -260.70% |
| 2024-06-30 | $-25.59M | $6.19M | (m) | $13.53M | (m) | -413.76% |
| 2024-03-31 | $-24.75M | $8.00M | (m) | $14.53M | (m) | -309.28% |
| 2023-12-31 | $-24.73M | $8.95M | (m) | $15.71M | (m) | -276.50% |
| 2023-09-30 | $-25.01M | $8.77M | (m) | $15.90M | (m) | -285.11% |
| 2023-06-30 | $-23.56M | $10.52M | (m) | $15.76M | (m) | -223.83% |
| 2023-03-31 | $-22.77M | $11.85M | (m) | $15.18M | (m) | -192.09% |
| 2022-12-31 | $-22.52M | $14.70M | (m) | $13.99M | (m) | -153.17% |
| 2022-09-30 | $-44.12M | $13.96M | (m) | $34.66M | (m) | -316.13% |
| 2022-06-30 | $-45.71M | $13.23M | (m) | $33.88M | (m) | -345.56% |
| 2022-03-31 | $-48.56M | $9.19M | (m) | $33.51M | (m) | -528.54% |
| 2021-12-31 | $-49.21M | $4.34M | (m) | $33.91M | (m) | -1133.63% |
| 2021-09-30 | $-26.86M | $3.53M | (m) | $11.74M | (m) | -761.20% |
| 2021-06-30 | $-26.74M | $1.83M | (m) | $12.50M | (m) | -1461.84% |
| 2021-03-31 | $-26.06M | (m) | (m) | $12.37M | (m) | (m) |
| 2020-12-31 | $-26.45M | $1.83M | (m) | $12.32M | (m) | -1448.36% |
| 2020-09-30 | $-27.44M | (m) | (m) | $13.20M | (m) | (m) |
| 2020-06-30 | $-29.13M | (m) | (m) | $13.90M | (m) | (m) |
| 2020-03-31 | $-33.55M | (m) | (m) | $16.33M | (m) | (m) |
| 2019-12-31 | $-38.88M | $3.52M | (m) | $17.95M | (m) | -1106.00% |
| 2019-09-30 | $-42.22M | (m) | (m) | $18.24M | (m) | (m) |
| 2019-06-30 | $-44.15M | (m) | (m) | $18.86M | (m) | (m) |
| 2019-03-31 | $-42.37M | (m) | (m) | $19.98M | (m) | (m) |
| 2018-12-31 | $-41.80M | $4.99M | (m) | $20.95M | (m) | -837.91% |
| 2018-09-30 | $-41.14M | $5.23M | (m) | $21.87M | (m) | -786.82% |
| 2018-06-30 | $-40.30M | $5.93M | (m) | $23.55M | (m) | -679.14% |
| 2018-03-31 | $-39.83M | $3.77M | (m) | $23.46M | (m) | -1056.70% |
| 2017-12-31 | $-38.90M | $3.46M | (m) | $24.02M | (m) | -1124.99% |
| 2017-09-30 | $-40.59M | $3.54M | (m) | $26.34M | (m) | -1146.02% |
| 2017-06-30 | $-42.39M | $3.35M | (m) | $26.20M | (m) | -1263.77% |
| 2017-03-31 | $-46.47M | $4.24M | (m) | $28.87M | (m) | -1096.01% |
| 2016-12-31 | $-58.97M | $5.92M | (m) | $36.11M | (m) | -995.56% |
| 2016-09-30 | $-69.41M | $6.30M | (m) | $41.88M | (m) | -1101.63% |
| 2016-06-30 | $-76.96M | $7.11M | (m) | $46.89M | (m) | -1082.78% |
| 2016-03-31 | $-76.06M | $7.84M | (m) | $47.02M | (m) | -969.60% |
| 2015-12-31 | $-65.81M | $7.04M | (m) | $42.60M | (m) | -935.32% |
| 2015-09-30 | $-58.51M | $7.45M | (m) | $41.08M | (m) | -785.04% |
| 2015-06-30 | $-53.50M | $6.34M | (m) | $38.45M | (m) | -844.16% |
| 2015-03-31 | $-53.05M | $5.44M | (m) | $38.45M | (m) | -974.94% |
| 2014-12-31 | $-50.68M | $5.24M | (m) | $37.53M | (m) | -966.63% |
| 2014-09-30 | $-65.57M | $5.26M | (m) | $35.49M | (m) | -1247.14% |
| 2014-06-30 | $-63.65M | $4.78M | (m) | $33.10M | (m) | -1330.62% |
| 2014-03-31 | $-58.74M | $4.89M | (m) | $29.62M | (m) | -1202.15% |
| 2013-12-31 | $-55.99M | $4.43M | (m) | $26.61M | (m) | -1262.54% |
| 2013-09-30 | $-33.75M | $3.76M | (m) | $22.18M | (m) | -896.56% |
| 2013-06-30 | $-29.53M | $4.05M | (m) | $20.32M | (m) | -728.70% |
| 2013-03-31 | $-27.47M | $3.88M | (m) | $19.33M | (m) | -708.30% |
| 2012-12-31 | $-25.00M | $3.92M | (m) | $18.12M | (m) | -638.53% |
| 2012-09-30 | $-23.40M | (m) | (m) | $-10.13M | (m) | (m) |
| 2012-06-30 | $-21.67M | (m) | (m) | $-11.21M | (m) | (m) |
| 2012-03-31 | $-20.58M | $4.16M | (m) | $-12.47M | (m) | -494.37% |
| 2011-12-31 | $-18.69M | $4.35M | (m) | $-13.70M | (m) | -429.10% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-9.85M | $3.68M | (m) | $-8.19M | (m) | -267.70% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-3.52M | $1.93M | (m) | $-3.18M | (m) | -182.86% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |